The conversation discusses the anticipation for updates on GT20029, a potential hair loss treatment. Users also mention using Minoxidil, finasteride, and RU58841.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.
GHK-Cu is discussed as a potential hair loss treatment, with claims of promoting hair growth and possibly reversing gray hair, though strong clinical evidence is limited. The user also mentions using Minoxidil, red light therapy, and microneedling.
Hair loss treatments are being tested on mice, with methods like minoxidil and stem cell therapy showing promising results. However, human trials are still years away, leading to humorous frustration about mice benefiting first.
PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.
A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.
KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.
PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.
A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.
Creatine may cause increased hair shedding due to androgen receptor sensitivity, despite limited evidence. The user is using dutasteride and minoxidil and seeks advice on whether shedding will stabilize, with suggestions including GHK-Cu and RU58841.
New hair loss treatments like GT20029, Clascoterone, and PP405 are being discussed, with concerns about how to apply multiple topicals alongside existing treatments like minoxidil and finasteride. Suggestions include creating a routine, mixing treatments, or minimizing redundancy in treatment stacks.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
The conversation discusses the potential of new hair loss treatments, with a focus on pyrilutamide, gt20029, and topical alfatradiol, and the possibility of improving their effectiveness through methods like increased concentration and microneedling. Dutasteride is also mentioned as a stronger option.
Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.
People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.
Hair loss treatments, including finasteride and minoxidil, as well as vitamins, supplements, and scalp biopsy. A joke was made about Feline Pattern Baldness in cats.
Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.
The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.
Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.
Experimenting with the effects of creatine and finasteride on DHT levels, as well as a discussion regarding the potential link between creatine supplementation and hair loss.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.
PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.
Significant hair regrowth was achieved using EssenGen 6-Plus with 6% minoxidil and 0.05% finasteride, along with Nizoral shampoo, over 12 weeks. No side effects were experienced, highlighting the benefits of a low dose.
The conversation is about hair regrowth progress using a combination of treatments: dutasteride, minoxidil, RU58841, ketoconazole, and monthly microneedling. The user reports that microneedling and topical minoxidil had the most impact on their hairline.